British Journal of Dermatology
04/30/2002
By David Loshak
Short-course betamethasone valerate, a potent steroid, and a longer course of a weaker preparation using hydrocortisone both control eczema in children equally well.
Researchers at the Universities of Nottingham and Ulster and Aston University, United Kingdom, carried out a randomised, double-blind, 18-week parallel group study to determine the efficacy of the two preparations in treating mild or moderate atopic eczema. They compared a three-day burst of betamethasone valerate 0.1% to 1.0% hydrocortisone for seven days, in treating disease exacerbations and maintaining remissions in 174 children recruited from 13 general practices.
The researchers evaluated two primary outcomes, the total number of scratch-free days and the number of disease relapses. Secondary outcomes included the median duration of the first disease relapse, the number of nights when sleep was not disturbed; disease severity, two quality-of-life measures and the number of treatment failures in each arm.
There were no differences between the two groups in any outcome measure. The median numbers of scratch free days were 118.0 with hydrocortisone and 117.5 with betamethasone. There was a median of one relapse in each group.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!